Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07798323

Noninvasive Imaging Biomarkers of Treatable Macrovascular Disease in Age-related Macular Degeneration.

The purpose of this prospective study is to investigate whether ophthalmic artery stenosis (narrowing of the ophthalmic artery) contributes to the development and progression of geographic atrophy (GA), an advanced form of dry age-related macular degeneration (AMD).

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Macular Degeneration Eye Diseases Retinal Degeneration Retinal Diseases

Age range

50 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Cleveland Clinic

Cleveland, Ohio, 44195, United States

Location status: Recruiting

Location contact

Sara Lautzenhiser Research Coordinator

CONTACT

[email protected]

216-444-3026

Scott Raymond, MD

PRINCIPAL_INVESTIGATOR

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 50-80 years of age
  • All genders
  • Asymmetric dry AMD with geographic atrophy in at least one eye and reduced disease severity in the other eye according to International Classification of Disease (ICD) codes
  • Treated at the Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio

Exclusion criteria

  • Poor image quality that limits quantification
  • GA extending beyond the borders of the SDOCT field of view.
  • Bilateral symmetric geographic atrophy.
  • Diagnosis of wet AMD.
  • Any retinal fluid at baseline.
  • Other concurrent retinal diseases
  • Vitreoretinal surgery.
  • Allergy to iodinated contrast agents.
  • Chronic kidney disease with eGFR < 60

Treatment and study plan

Primary outcomes

  1. To demonstrate the ability to quantify ophthalmic artery stenosis using a commercially available, non-invasive imaging modality, PC-CTA.

    Time frame: From enrollment to the end of the 12-month study period.

Secondary outcomes

  1. To provide compelling evidence for a connection between ophthalmic artery stenosis and OCT markers of dry AMD disease severity and progression.

    Time frame: From enrollment to the end of the 12-month study period.

Study contacts

Contact information is provided by the study sponsor or research team.

Sara Lautzenhiser Research Coordinator

CONTACT

[email protected]

216-444-3026

Sponsors and collaborators

Lead sponsor

Scott Raymond

Other

Registry information

Important dates

Study start
2026
Primary completion
2028
Study completion
2028
First posted
Sep 1, 2026
Registry last updated
Sep 3, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.